Volume | 468,971 |
|
|||||
News | - | ||||||
Day High | 18.11 | Low High |
|||||
Day Low | 17.50 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Kiniksa Pharmaceuticals Ltd | KNSA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
17.565 | 17.50 | 18.11 | 17.61 | 17.86 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
7,021 | 468,971 | $ 17.86 | $ 8,378,155 | - | 10.645 - 22.10 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:52:02 | 1 | $ 17.00 | USD |
Kiniksa Pharmaceuticals Ltd Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.24B | 70.62M | - | 270.26M | 14.08M | 0.20 | 88.31 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Kiniksa Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical KNSA Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 16.99 | 18.61 | 16.56 | 17.34 | 440,379 | 0.62 | 3.65% |
1 Month | 20.06 | 20.125 | 16.56 | 17.81 | 368,130 | -2.45 | -12.21% |
3 Months | 17.69 | 22.10 | 16.56 | 19.41 | 376,693 | -0.08 | -0.45% |
6 Months | 15.15 | 22.10 | 14.12 | 18.18 | 429,989 | 2.46 | 16.24% |
1 Year | 11.48 | 22.10 | 10.645 | 17.17 | 433,702 | 6.13 | 53.40% |
3 Years | 16.41 | 22.10 | 7.36 | 14.23 | 392,452 | 1.20 | 7.31% |
5 Years | 15.18 | 33.00 | 5.01 | 15.31 | 354,255 | 2.43 | 16.01% |
Kiniksa Pharmaceuticals Description
Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its clinical-stage product candidates include Rilonacept, for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; Vixarelimab; and KPL-404. |